EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The impact of phenotypic- versus target-based approaches in antimalarial drug discovery in the last two decades (2005–2025)

Peter Mubanga Cheuka iD, Godfrey Mayoka iD, Dickson Mambwe iD, Ameera Mohammed Dawoodjee, Ayanda Zulu iD

Future Medicinal Chemistry · 2025

DOI: 10.1080/17568919.2025.2580928 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, 2025. Verfasst von Peter Mubanga Cheuka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pure and Applied Chemistry, School of Natural and Applied Sciences, University of Zambia, Lusaka, Zambia. Hauptthemen laut MEDLINE: Antimalarials. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Malaria causes major mortality, with the downward trend in the number of cases and deaths seemingly stalled. In 2023, 95% of global malaria deaths were reported in the World Health Organization (WHO) African region, with children under the age of 5 years being the most affected. Artemisinin-combination therapies (ACTs), the currently recommended first-line treatments, are threatened by resistance, which has so far been reported in Africa and Southeast Asia. Thus, new drugs are needed. AREAS COVERED: In this review, we discuss the two main antimalarial drug discovery paradigms (phenotypic- and target-based drug discovery approaches) and highlight their impact in antimalarial drug development, as judged by the clinical candidates these two drug development philosophies have delivered in the last two decades. We also highlight the geographical imbalance in contributions to research and development (R&D) efforts that led to the development of these clinical candidates. EXPERT OPINION/COMMENTARY: While phenotypic-based drug discovery outperformed the target-based approach, we propose some strategies to improve chances of success in the latter strategy. Furthermore, although antimalarial drug discovery and development has seen an encouraging shift toward more collaborations among industry, academia, and product development partners, R&D in this space remains concentrated in the global north.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsHumansWorld Health OrganizationAfricaDrug DiscoveryPhenotypeAsia, Southeastern

Stichwörter der Autor:innen

Phenotypic-based drug discoveryantimalarialclinical candidatescollaborative drug discoverymalariatarget-based drug discovery

Substanzen

Antimalarials

Autor:innen und Institutionen

  • Department of Pure and Applied Chemistry, School of Natural and Applied Sciences, University of Zambia, Lusaka, Zambia.
  • Department of Pharmacology and Pharmacognosy, School of Pharmacy, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
  • Helmholtz Institute for Pharmaceutical Research, Helmholtz Centre for Infection Research, Saarbrucken, Germany.

ORCID-Profile: Peter Mubanga Cheuka, Godfrey Mayoka, Dickson Mambwe, Ayanda Zulu

Zitieren

APA

Cheuka, P. M., Mayoka, G., Mambwe, D., Dawoodjee, A. M., & Zulu, A. (2025). The impact of phenotypic- versus target-based approaches in antimalarial drug discovery in the last two decades (2005–2025). Future Medicinal Chemistry. https://doi.org/10.1080/17568919.2025.2580928

Vancouver

Cheuka PM, Mayoka G, Mambwe D, Dawoodjee AM, Zulu A. The impact of phenotypic- versus target-based approaches in antimalarial drug discovery in the last two decades (2005–2025). Future Medicinal Chemistry. 2025. doi:10.1080/17568919.2025.2580928

BibTeX
@article{Cheuka2025,
  author = {Cheuka, Peter Mubanga and Mayoka, Godfrey and Mambwe, Dickson and Dawoodjee, Ameera Mohammed and Zulu, Ayanda},
  title = {The impact of phenotypic- versus target-based approaches in antimalarial drug discovery in the last two decades (2005–2025)},
  journal = {Future Medicinal Chemistry},
  year = {2025},
  doi = {10.1080/17568919.2025.2580928}
}
Kostenlos starten →